Content area

|
|

Off-label-brug af psykofarmaka til børn og unge i Danmark

Forfattere
Anne Katrine Pagsberg1, 2 & Per Hove Thomsen3, 4 1) Børne- og Ungdomspsykiatrisk Center, Forskningsenheden, Region Hovedstadens Psykiatri 2) Det Sundhedsvidenskabelige Fakultet, Københavns Universitet 3) Børne- og Ungdomspsykiatrisk Center, Aarhus Universitetshospital 4) Institut for Klinisk Medicin, Aarhus Universitet Ugeskr Læger 2017;179:V05170355
Reference: 
Ugeskr Læger 2017;179:V05170355
Blad nummer: 
Sidetal: 
2-6
Off-label prescription of psychopharmacological drugs for children and adolescents
Despite regulatory initiatives, psychopharmacological treatment of adolescents is challenged by missing trial data on efficacy and safety. An estimated mean off-label prescription rate of 30-40% in Danish clinical child- and adolescent mental health services (MHS) has been found. Lowest rates were found for ADHD drugs (2-3%) and highest for antipsychotics (96%) and melatonin (100%). The use of melatonin is growing, while the use of other psycho­pharmacological drugs seems stabilizing or decreasing in spite of more adolescents treated in Danish MHS.

💬 0 Kommentarer

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Per Kristian Kruhøffer | 21/04
1 Kommentar
af Kristian Rørbæk Madsen | 21/04
6 kommentarer
af Alice Kunkel | 21/04
1 Kommentar
af Klaus Larsen | 18/04
2 kommentarer
af Elo Aagaard Rasmussen | 17/04
5 kommentarer
af Jan Peter Baark | 15/04
3 kommentarer
af Mogens Stubkjær Hüttel | 15/04
2 kommentarer
af Tem Salkvist Jørgensen | 13/04
1 Kommentar